The FDA has released a request for information (RFI)soliciting comments from the public, particularly veterinarians, related to the use of cannabis-derived products (CDP) in animals. The focus of this RFI is on cannabidiol (CBD) products and other products derived from hemp.The FDA is trying to better understand what veterinarians are experiencing related to CDPs in their patients, such as: general patterns of use (i.e., animal species, brands, formulations, doses, indications for use), quality standards, benefits of use, potential drug interactions, adverse events and safety problems, and toxicological concerns.
The Federal Register notice about the RFI contains instructions for submitting comments. FDA will fully consider all comments, including comments submitted anonymously. The comment period for this RFI opens on January 16, and will be open for 90 days. If you have relevant responses to the questions in the RFI, please submit them no later than April 16, 2025.